Jul 7, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Encouraging Phase 2 Interim Data For Elotuzumab In Relapsed Multiple Myeloma Presente
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2425423" data-attributes="member: 124445"><p>Abbott (NYSE: ABT) and Bristol-Myers Squibb Company (NYSE: BMY) announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone. ORR, the primary endpoint of the Phase 2 portion of the study, was defined as partial response or better and assessed using International Myeloma Working Group (IMWG) criteria...<a href="http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/ERq2VXprIFI" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/ERq2VXprIFI/3NPC" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2425423, member: 124445"] Abbott (NYSE: ABT) and Bristol-Myers Squibb Company (NYSE: BMY) announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma who received elotuzumab plus lenalidomide and low-dose dexamethasone. ORR, the primary endpoint of the Phase 2 portion of the study, was defined as partial response or better and assessed using International Myeloma Working Group (IMWG) criteria...[URL="http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/0/da"][IMG]http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/1/da"][IMG]http://feedads.g.doubleclick.net/~a/b2WHtCLS1Yfu6KfLQluqXYIw05g/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/ERq2VXprIFI[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/ERq2VXprIFI/3NPC]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top